Mumbai, April 25, 2026: Boehringer Ingelheim India has signed a Memorandum of Understanding (MoU) with NIPER Hajipur to strengthen pharmaceutical research, education, and innovation through a five-year collaboration.
The partnership aims to expand research capabilities in eastern India by enabling access to global scientific resources, joint research initiatives, and structured capability-building programmes. The MoU was signed in the presence of officials from the Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers.
As part of the collaboration, researchers and faculty at NIPER Hajipur will gain access to opnMe®, Boehringer Ingelheim’s global open science platform. This platform provides well-characterised pre-clinical tool compounds free of cost to support scientific research. The initiative extends access to such resources at scale in eastern India for the first time.
The partnership will focus on areas including pharmaceutical technologies, novel drug delivery systems, academic exchange, and collaborative research. It is also aligned with the Government of India’s Biopharma SHAKTI initiative, which aims to strengthen innovation-led growth in the pharmaceutical sector and position NIPER institutions as centres of excellence.
Shri Manoj Joshi, Secretary, Department of Pharmaceuticals, highlighted the importance of industry-academia collaboration in strengthening research and improving access to quality healthcare. He noted that India’s pharmaceutical sector is transitioning towards a value-driven, innovation-led ecosystem supported by policy and institutional partnerships.
Prof. K. Ruckmani, Director, NIPER Hajipur, said, “NIPER Hajipur sits at the heart of one of India’s most populous regions, and our mandate is to build pharmaceutical research and talent capability that serves Bihar, eastern India and the country at large. Our partnership with Boehringer Ingelheim India and particularly the access it brings to the opnMe ® open science platform, gives our researchers and students direct exposure to globally validated pre-clinical tools and world-class R&D collaboration. This is a meaningful step in realising the Government of India’s vision of building self-reliant, geographically distributed pharmaceutical innovation capability across the country.”
Meenal Gauri, Managing Director, Boehringer Ingelheim India, added, “NIPERs have been identified by the government as centres of excellence for Biopharma SHAKTI, and our view is simple: the greater the number of talented Indian researchers engaged in this mission, the stronger the outcomes for the country. That is why, after our partnership with NIPER Raebareli, we are proud to extend opnMe® access to the researchers at NIPER Hajipur, giving them the same well-characterised molecules, free of charge, that scientists across the world use for discovery. We see this as the deepening of a long-term commitment to India’s pharmaceutical education network, and our contribution to the Viksit Bharat and Biopharma SHAKTI vision.”
The collaboration is structured on a non-profit, non-commercial basis, focusing on strengthening research ecosystems and developing future-ready scientific talent.
 1 1.png)
x
.jpg)
.png)
